This phase 1 dose-escalation study is designed to evaluate the safety and tolerability of talazoparib in combination with 177Lu-DOTA-Octreotate peptide receptor radionuclide therapy (PRRT) in patients with metastatic pancreatic or midgut neuroendocrine tumour (NET).
Patient must be > or equal to18 years of age and must have provided written informed consent.
Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 2
Histologically confirmed Grade 2 NET, Ki-67 of 3-20%, from pancreatic or intestinal origin.
Patient clinically suitable for PRRT
Surgery or radiotherapy within <3 weeks of registration. Patients must have recovered from any effects of any major surgery.
Any prior exposure to peptide receptor radionuclide therapy (177Lu, 111In or 90Y labelled), PARPi, immunotherapy
Uncontrolled intercurrent illness that is likely to impede participation and /or compliance
Other malignancies unless curatively treated with no evidence of disease within previous 3-years other than adequately treated non-melanoma skin cancer or melanoma in situ.